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Myoglobin depletes renal adenine nucleotide pools in the
presence and absence of shock
RICHARD A. ZAGER
Department of Medicine, University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Myoglobin depletes renal adenine nucleotide pools in the presence and
absence of shock. To assess whether myoglobin adversely affects renal
adenylate poois, rats were infused with purified myoglobin (50 mg/100 g
body wt) for two hours and renal ATP, ADP, and AMP levels were
measured in the absence of shock, after 25 minutes of hemorrhagic
shock (55 to 60 mm Hg) or 30 minutes post-recovery. In the absence of
shock, myoglobin lowered ATP by 24% (assessed 65 mm post-infusion)
without affecting renal blood flow (RBF). This effect was completely
blocked by deferoxamine (DFO) treatment and it could not be repro-
duced by ribonuclease infusion (a non-Fe containing, but filtered,
protein). Myoglobin + shock caused a three- to fourfold greater decline
in ATP than did shock alone despite comparable RBFs. Shock plus
myoglobin, but neither one alone, induced substantial S l/S2 proximal
tubular morphologic damage and a severe reduction in creatinine
clearance, confirming synergistic injury. Ribonuclease completely re-
produced myoglobin's effect on shock-induced adenylate profiles. DFO
hydroxyl radical scavenger therapy (Na benzoate) did not block the
myoglobin shock effect on adenylate pools. Post-shock adenylate
recovery was not compromised by myoglobin pre-treatment. If renal
artery occlusion (RAO), rather than shock, was used as the ischemic
challenge, myoglobin had no discernible impact on adenine nucleotide
content. This study concludes that: 1) myoglobin modestly lowers
baseline adenylate pools due to an Fe dependent mechanism; 2)
myoglobin drastically accentuates shock-induced adenylate depletion
by a non-hemodynamic/non-Fe dependent mechanism; 3) myoglobin
nephrotoxicity cannot be attributed solely to tissue iron loading; and 4)
the RAO model can completely mask important influences on ischemic
cellular energetics. This needs to be recognized when the RAO model is
used to study ischemic ARF.
For almost 50 years, it has been recognized that myohemo-
globinemia (uria) can exacerbate ischemic renal injury [1, 21.
However, the reason for this interaction has remained incom-
pletely defined. To address this issue, our laboratory has
previously studied the influence of both myoglobin and hemo-
globin on renal artery occlusion (RAO)- induced ischemic acute
renal failure (ARF) in rats [3, 4]. On the basis of these studies
we have concluded that: 1) both myoglobin [3] and hemoglobin
[4], administered prior to RAO, can worsen ischemic tubular
necrosis; 2) this necrosis-potentiating effect may not be heme
protein specific since non-Fe containing low molecular weight
proteins (such as, ribonuclease, cationic/anionic lysozyme) had
a comparable adverse effect [3]; 3) myoglobin [3] and hemoglo-
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bin [4] can exacerbate ischemia-induced intratubular obstruc-
tion by providing additional matrix for cast formation; and 4)
although iron chelation therapy (deferoxamine, or DFO) can
protect against heme protein-induced injury in the absence of
ischemia [41, it may not lessen the heme pigment-ischemia
interaction [4]. However, this latter conclusion must be consid-
ered tentative since Paller reported that DFO protected against
hemoglobin-RAO induced ARF [5].
A potential problem with studying the heme protein-ischemic
synergy using the RAO model is that any influence that heme
pigments might have on tubular energetics may be either
masked or negated by total vascular occlusion. This is because
vascular clamping causes a virtual maximal rate of decline in
renal ATP concentrations [6]. Thus, any effect of heme proteins
on ischemic ATP content may be overwhelmed, and hence, not
detected. Furthermore, the relevant issue is not whether heme
proteins affect RAO-induced adenylate profiles but rather,
whether they alter renal energetics during hypoperfusion. This
is because clinical rhabdomyolysis causes intravascular volume
depletion, and hence renal hypoperfusion [7], not a complete
blood flow cessation state.
Some experimental evidence suggests that myohemoglobin-
uria may, indeed, adversely impact renal energetics during a
hypoperfusion state. First, modest renal ATP depletion occurs
during the initiation phase of glycerol-induced myohemoglobin-
uric ARF [8, 9]. Second, heme proteins (or possibly some other
muscle/red cell constituent) can cause renal vasoconstriction
[10, 11], potentially augmenting the renal ischemia induced by
volume depletion. Third, hense proteins have a direct nephro-
toxic effect [4, 12], possibly due to heme Fe-driven lipid
peroxidation via the Haber-Weiss reaction [5, 13—15]. If so,
then oxidant tissue injury could impair tubular cell energy
production during a hypoperfusion state, particularly since
mitochondria are highly vulnerable to peroxidative damage
[16].
Given the potential limitations inherent to assessments of
cellular energetics during RAO, the present study was under-
taken to determine whether myoglobin does, in fact, adversely
effect tubular cell energetics, thereby predisposing to ischemic
tissue injury. The following specific questions were addressed:
1) Does myoglobin lower renal ATP content independent of
volume depletion/hypotension? 2) Does myoglobin exacerbate
renal ATP depletion during a hypotensive period? 3) If so, is
this heme protein-ischemic synergy mediated by a potentiation
of hypotension-induced renal vasoconstriction? 4) Can DFO/
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antioxidant therapy mitigate adverse effects of myoglobin on
renal cellular energetics? and 5) Does RAO truly mask impor-
tant heme protein effects on ischemic adenylate pools? If so,
this would indicate that the RAO model has a major limitation
for studying heme pigment-ischemic interactions.
Methods
General procedures
Surgery. Female Sprague-Dawley rats (175 to 250 g, Bantim
Kingsman, Fremont, California, USA) housed under standard
laboratory conditions, were used for all experiments. Following
induction of anesthesia (pentobarbital, 40 mg/kg), a left carotid
artery catheter (PESO), a right jugular vein catheter (PE5O), and
a lower abdominal aortic catheter (PE9O) were placed, the latter
through a midline abdominal incision. The aortic catheter was
inserted just above the femoral bifurcation, special care being
taken to keep the catheter tip below the origin of the renal
arteries. Following catheter insertion, the abdomen was closed
with surgical clamps. The aortic catheter was attached to a
heparinized syringe for blood withdrawal in order to induce
hemorrhagic shock. The carotid catheter was used to continu-
ously monitor mean arterial pressure (MAP) [171. The jugular
catheter was used for i.v. infusion.
Adenine nucleotide analysis. Upon completing selected pro-
tocols described below, the abdomen was re-opened and the left
kidney, previously freed up from perinephric tissues at the time
of aortic catheter placement, was rapidly excised by transecting
the renal pedicle and it was instantly frozen (< 0.5 sec) by
immersion in liquid nitrogen. After freezing, a sample of corti-
cal/outer medullary tissue was chipped off the kidney and this
sample was extracted and analyzed for ATP, ADP, and AMP by
HPLC, as previously described [181. (Note: Values obtained on
immersion frozen kidneys are essentially identical to those
found in in vivo freeze clamped tissues, the latter method being
typically employed in this laboratory [31. Immersion freezing
was used in this study because the kidney manipulation needed
just prior to freeze clamping can induce artifacts in adenylate
values by compromising renal blood flow under conditions of
shock.) All adenine nucleotide concentrations were expressed
as smol/g tissue dry weight. Total adenine nucleotide (TAN:
the sum of ATP + ADP + AMP), the adenylate energy charge
[AEC: (ATP + 1/2ADP)/TAN] and ATP/ADP ratios were calcu-
lated. Total adenylate high energy phosphate (HEP) per g tissue
dry wt was also quantified as: ATP x 2 + ADP (based on the
fact that ATP and ADP have 2 and 1 high energy phosphates per
molecule, respectively).
Specific protocols
Blood pressure controlled hemorrhagic shock experiments.
Seven rats received a two hour i.v. infusion of horse skeletal
muscle myoglobin [Sigma Chemical Company, St. Louis, Mis-
souri, USA, M-0630; 50 mg protein per 100 g of body wt,
dissolved (30 mg/ml) in 5% dextrose/H20 (D5W)]. At the end of
the two hour infusion, blood was withdrawn from the aortic
catheter, lowering MAP to 55 to 60 mm Hg over 10 minutes.
This target blood pressure range was maintained for the next 25
minutes (withdrawing or re-infusing small quantities of blood
from the aortic catheter as necessary). After completing this 25
minute shock period, the left kidney was resected for adenine
nucleotide analysis. Six rats infused only with D5W x two
hours and subjected to the same shock protocol served as
controls,
Recovery phase experiments. Six rats were subjected to the
above myoglobin infusion/hemorrhagic shock experiment. Af-
ter 25 minutes at 55 to 60 mm Hg, enough blood (maintained at
37°C) was re-infused to restore MAP to normal (120 mm Hg)
within five minutes. The latter hemodynamic condition was
maintained for 30 minutes and then the left kidneys were
resected and processed for adenine nucleotides. Eight rats
pre-treated with a two hour infusion of D5W alone, subjected to
shock, and then to 30 minutes of hemodynamic recovery served
as controls.
Blood volume controlled hemorrhagic shock experiments, In
the above experiments, the myoglobin treated rats required
slightly more blood withdrawal (—-1 ml) to maintain the 55 to 60
mm Hg MAP target range than did the controls (Results). Thus,
the following experiment contrasted shock-induced renal ade-
nylate responses in myoglobin and D5W pre-treated rats when
the amount of blood withdrawn, not the blood pressure, was
controlled. Ten rats, half infused with myoglobin and half
infused with D5W for two hours, were subjected to a 2.25
ml/lOO g body wt hemorrhage. The blood was withdrawn
continuously over the 25 minute period irrespective of blood
pressure (which was continuously recorded). After 25 minutes,
the left kidneys were harvested for adenine nucleotide analysis.
Effect of myoglobin infusion on renal adenine nucleotide
content independent of shock. The following experiment eval-
uated how myoglobin infusion, administered over the time
frame utilized in the above experiments, influences renal ade-
nylate pools independent of shock/reperfusion. Fourteen rats
were subjected to the two-hour myoglobin infusion followed by
either a 35 minute (N = 6) or 65 minute (N = 8) non-infusion
period (time matched to the above shock/reperfusion protocols,
respectively). Then, the left kidneys were harvested for adenine
nucleotide analysis. The results were contrasted to values
observed in 13 D5W infused time matched controls (7 rats, 35
mm post-infusion; 6 rats, 65 mm post-infusion).
Renal blood flow (RBF) responses to hemorrhagic shock.
Fourteen rats were subjected to the 55 to 60 mm Hg hemor-
rhagic shock protocol, seven pre-treated with myoglobin and
seven pre-treated only with D5W. Ten minutes prior to the start
of blood withdrawal an electromagnetic flow probe [17] was
positioned around the left renal artery. After a baseline value
was established, the MAP was lowered into the 55 to 60 mm Hg
range. Baseline RBF and RBF at 55 to 60 mm Hg for the two
groups were contrasted by flow meter technology [17].
Effects of DFO on myoglobin induced adenylate pool
changes
a) Influence on adenylate pools independent of shock. Since
myoglobin infusion lowered renal adenylate pools independent
of shock (Results) the following experiment evaluated whether
DFO could mitigate this effect. Six rats were infused with
myoglobin over two hours as noted previously, but they re-
ceived 60 mg of DFO i.m. (in 0.9 ml H20) during the course of
the infusion (20 mg at the start; 20 mg at 1 hr; 20 mg at end of
infusion). After a 65-minute latency period, the left kidneys
were harvested for adenine nucleotide analysis. The results
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were contrasted to those observed in the rats subjected to two
hours of myoglobin infusion followed by a 65 minute latency
period, as detailed above.
b) Influence of DFO with/without Na benzoate on shock-
induced adenylate pools. The following experiment assessed
whether antioxidant therapy preserves adenylate pools in rats
infused with myoglobin and then subjected to shock. Ten rats
were infused with myoglobin and all were treated with DFO, as
noted above. Four of the rats received Na benzoate (an
hydroxyl radical scavenger) along with DFO, the former being
added to the myoglobin infusion (total dose 150 mg/kg body wt).
After completing the two-hour myoglobin infusion, all 10 rats
were subjected to the 55 to 60 mm Hg shock protocol, followed
immediately by left kidney removal for adenine nucleotide
analysis. The results were contrasted to those observed in the
rats subjected to the myoglobin infusion/shock protocol, dis-
cussed above.
Effect of ribonuclease infusion on adenylate pools in the
presence and absence of shock
To assess whether myoglobin's effects on renal energy pools
could be mimicked by a non Fe containing low molecular
weight (filterable) protein, six rats were infused for two hours
with ribonuclease (Sigma, R-5503; molecular wt 13,400), ex-
actly as detailed above for myoglobin and then the 55 to 60 mm
Hg shock protocol was conducted. At the end of shock the left
kidneys were removed for adenine nucleotide analysis. Five
D5W pretreated rats subjected to 55 to 60 mm Hg of shock
served as controls. To assess whether ribonuclease, like myo-
globin, lowers adenylate poois independently of shock, three
rats received the two-hour ribonuclease infusion followed by a
65-minute latency period, and then the left and right kidneys
were simultaneously resected for adenylate analysis.
Renal histology
Six rats were subjected to two hours of myoglobin infusion
and 25 minutes of 55 to 60 mm Hg shock. Then, the kidneys
were fixed in vivo with 1.25% glutaraldehyde by retrograde
aortic perfusion [17]. A coronal section of one kidney per rat,
containing all anatomic regions, was post-fixed in 10% buffered
formaldehyde. Five micrometer paraffin imbedded sections
were cut and stained with hematoxylin and eosin and examined
by light microscopy. The findings were contrasted to those
observed in: 1) in vivo perfusion fixed kidneys obtained from
six rats subjected to D5W infusion and 55 to 60 mm Hg
hemorrhagic shock; and 2) perfusion fixed kidneys from five
rats infused with myoglobin alone followed by a 35-minute
latency period (time matched to the above experiments).
Creatinine clearance assessment
To assess whether differences in histology induced by the
three above protocols have functional correlates, rats were
subjected to myoglobin infusion plus shock (N = 4), shock
alone (N = 3), or myoglobin infusion alone (N = 3), as just
described. After completing shock, the blood was re-infused
over 30 minutes, the bladder was then emptied, and a one-hour
urine collection was completed [17]. The myoglobin/no shock
group had a time matched one-hour urine collection. At the end
of urine collection, a plasma creatinine and the one-hour urine
creatinine concentrations were measured and creatinine clear-
ances (Ccr) determined.
Effect of myoglobin on cellular energetics during RAO
The following experiment tested our hypothesis that potential
myoglobin effects on ischemic cellular energetics are masked by
using the RAO model. Ten rats were subjected to a two hour
i.v. infusion, half with myoglobin and half with D5W, as noted
above. Thirty minutes later, five minutes of left RAO was
induced followed by kidney resection without allowing reflow.
All kidneys were analyzed for adenine nucleotides as noted
above to assess whether significant differences existed between
the two groups. Of note, a five minute ischemic challenge was
utilized since after more prolonged RAO, near nadir ATP
values are achieved [19], presumably making it more difficult to
discern a myoglobin effect.
Statistical analysis
All values are given as means 1 SEM. Comparison's
between two groups were made by unpaired Student's t-test. If
more than two groups were contrasted, the Bonferroni correc-
tion method was applied. Blood flow data were analyzed by one
way ANOVA for repeated measures. Significance was judged
by a P of <0.05.
Results
Effect on myoglobin on adenine nucleotides independent of
shock
To facilitate presentation of the myoglobin/shock/reperfusion
data, the results with myoglobin infusion without shock/reper-
fusion are presented first (Table 1). Myoglobin infusion signif-
icantly lowered renal adenine nucleotide pools, as reflected by
significant.decrements in ATP, ADP, TAN, and HEP values at
both two hours-35 minutes and three hours-five minutes after
the start of the infusion. This loss of nucleotide was progressive
with time since the three hour-five minute values were lower
than the two hour-35 minute values (Table 1). Despite the
decrease in adenylate pools, the adenylate energy charge and
the ATP/ADP ratios did not decline (as one would expect with
tissue ischemia). In fact, the ATP/ADP ratio actually increased,
reaching statistical significance by three hours-five minutes
(myoglobin: 3.44 0.10 vs. controls 2.63 0.17; P < 0.002).
DFO treatment essentially abolished the adverse effect of
myoglobin on non-ischemic renal adenylate pools. ATP, ADP,
TAN, and HEP were all significantly preserved (group e, Table
1) such that these values no longer significantly differed from
control values (group d, Table 1). Interestingly, the rnyoglobin
induced elevation in the ATP/ADP ratio was not affected by the
DFO treatment.
Effect of myoglobin on blood pressure controlled shock (55 to
60 mm Hg) experiments
The 55 to 60 mm Hg shock protocol had a relatively small
effect on renal adenylate pools in the D5W controls, with end
shock ATP and total HEP equalling —75% of normal kidney
values (Table 2). Myoglobin pre-treatment drastically exagger-
ated the shock-induced adenylate loss, ATP and HEP falling to
—20% of normal values. However, not all of the adenylate pool
loss in the myoglobin/shock group can be attributed to an
114 Zager: Myoglobin depletes adenine nucleotides
Table 1. Effect of myoglobin infusion on renal adenylate pools in the absence of shock and the influence of DFO treatment
N ATP ADP AMP TAN HEP AEC
ATP
ADP
2 hrs-35 mm
a) Myoglobin 6 7.60
(0.25)
2.50
(0.24)
0.58
(0.11)
10.67
(0.29)
17.70
(0.40)
0.83
(0.02)
3.17
(0.29)
b) Controls 7 8.91
(0.36)
3.25
(0.20)
0.75
(0.38)
12.89
(0.47)
21.03
(0.77)
0.82
(0.01)
2.81
(0.23)
P (a vs. b) <0.02 <0.05 NS <0.01 <0.01 NS NS
3 hrs-5 mm
c) Myoglobin 8 6.71
(0.28)
1.95
(0.06)
0.53
(0.03)
9.20
(0.32)
14.75
(0.67)
0.84
(0.01)
3.44
(0.10)
d) Controls 6 8.79
(0.54)
3.36
(0.15)
0.76
(0.07)
12.90
(0.58)
20.90
(1.10)
0.81
(0.01)
2.63
(0.17)
P (c vs. d) <0.02 <0.002 <0.02 <0.002 <0.002 NS <0.002
e) Myoglobin + DFO 6 8.99
(0.58)
2.59
(0.16)
0.57
(0.03)
12.15
(0.73)
20.57
(1.30)
0.85
(0.005)
3.47
(0.11)
P (C vs. e) <0.02 <0.02 NS <0.02 <0.002 NS NS
All mean values are presented as mo1/g dry tissue weight (1 SEM in parentheses). Abbreviations are: TAN, total adenine nucleotide (ATP +
ADP + AMP); HEP, adenylate high-energy phosphate (ATP x 2 + ADP); AEC, adenylate energy charge (ATP + '/2ADPITAN). Statistics are by
unpaired Student's t-test with Bonferroni correction, as indicated.
Table 2. Pressure controlled (55 to 60 mm Hg) hemorrhagic shock experiments
ATP
N ATP ADP AMP TAN HEP HEP AEC ADP
Normal values 13 8.85
(0.30)
3.30
(0.12)
0.75
(0.05)
12.90
(0.35)
21.00
(0.64)
0
(0)
0.81
(0.01)
2.70
(0.28)
Shock (55—60 mm Hg)
a) Controls 6 6.51
(0.77)
3.21
(0.14)
1.57
(0.44)
11.28
(0.50)
16.38
(1.61)
4.62
(1.61)
0.71
(0.05)
2.01
(0.19)
b) Myoglobin 7 1.50
(0.37)
1.55
(0.19)
2.88
(0.20)
5.93
(0.41)
4.78
(0.85)
12.92
(0.85)
0.36
(0.05)
0.90
(0.18)
P (a vs. b) <0.002 <0.002 <0.04 <0.002 <0.002 <0.002 <0.002 <0.002
c) Myoglobin/antioxidants
P (b vs. c)
10 1.50
(0.21)
NS
1.53
(0.16)
NS
3.16
(0.13)
NS
6.19
(0.33)
NS
4.53
(0.58)
NS
16.07
(0.58)
<0.01
0.35
(0.03)
NS
0.94
(0.08)
NS
Recovery
d) Myoglobin
e) Controls
6
8
3.42
(0.60)
5.82
(0.30)
1.43
(0.22)
2.68
(0.25)
0.62
(0.10)
0.95
(0.20)
5.48
(0.78)
9.44
(0.55)
8.27
(1.40)
14.30
(0.76)
6.37
(1.38)
6.70
(0.76)
0.75
(0.03)
0.77
(0.02)
2.37
(0.22)
2.27
(0.19)
P <0.01 <0.01 NS <0.001 <0.01 NS NS NS
Abbreviations are in Table 1. Other abbreviations are: LHEP, change in HEP from non-shock values; antioxidants, DFO Na benzoate. The
normal values presented are a pool of those presented in Table 1 and are presented for reference value only.
exaggerated ischemic response since, as noted above, myoglo-
bin infusion in the absence of shock caused an approximate 15%
drop in HEP (21 vs. 17.7 rmo1/g; Table 1, group a vs. b).
To assess how much REP was lost during shock (correcting
for the fact that HEP fell from myoglobin infusion alone), the
change in HEP (LHEP) was calculated. For the myoglobin rats,
this was done by subtracting the observed HEP values for each
rat at the end of 25 minutes of shock from the amount of HEP
previously determined to be present after two hours-35 minutes
of myoglobin treatment (17.7 prnol/g; from Table 1, group a).
For the controls, the starting HEP value was taken as 21 rmol/g
(Table 1, group b). As shown in Table 2, the HEP loss was
approximately three times greater in the myoglobin versus the
control group (P < 0.002). The worsened adenylate pool
response in the myoglobin group was also reflected by AEC and
ATP/ADP ratio values which were only —50% of those ob-
served in the control shock group (P < 0.002). [Of note, these
values need not be corrected for starting values since they
showed no decline with myoglobin infusion in the absence of
shock (Table 1). Thus, the utility of the AEC and ATP/ADP
ratio determinations is that each kidney serves as its own
control].
Effect of antioxidant therapy on myoglobin-shock induced
adenylate depletion
The DFO and DFO/Na benzoate protocols induced virtually
identical results and thus, for the sake of simplicity, these two
groups were combined, the data being presented in Table 2,
group c. No preservation of adenylate pools was evoked by
these treatments, almost the same values being found in these
rats (group c) and the myoglobin-shock group (group b). If
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Table 3. Volume controlled hemorrhagic shock experiments
ATP MAP
N ATP ADP AMP TAN HEP LHEP AEC ADP T end
2.25 ml/100 g
hemorrhage
myoglobin 5 2.93
(0.53)
2.54
(0.27)
3.41
(0.61)
8.90
(0.55)
8.42
(1.34)
9.32
(1.34)
0.47
(0.06)
1.12
(0.11)
114
(10)
73
(7)
controls 5 6.19
(0.56)
3.42
(0.19)
2.22
(0.52)
11.83
(0.32)
15.81
(1.19)
5.18
(1.18)
0.67
(0.05)
1.82
(0.18)
73
(5)
42
(5)
P <0.01 <0.05 NS <0.01 <0.01 <0.05 <0.05 <0.01 <0.01 <0.01
Abbreviations are in Tables 1 and 2. Other abbreviations are: MAP (mean arterial pressure), T = mean for the 25 mm blood withdrawal period;
end = at end of the 25 mm period. Statistics are by unpaired Student's i-test.
Table 4. Ribonuclease (RNAase)/shock experiments
ATP
N ATP ADP AMP TAN HEP HEP AEC ADP
Controls/shock 5 7.89
(0.51)
3.30
(0.18)
1.50
(0.19)
12.69
(0.53)
19.10
(1.14)
2.21
(0.95)
0.75
(0.02)
2.40
(0.14)
RNAase/shock 6 2.80
(0.64)
2.19
(0.31)
2.58
(0.11)
7.57
(0.87)
7.79
(1.59)
13.21
(1.59)
0.48
(0.06)
1.17
(0.17)
P <0.001 <0.02 <0.001 <0.001 <0.001 <0.001 <0.01 <0.001
Abbreviations are in Table 1. Statistics are by unpaired Student's i-test. The LHEP was calculated using a normal starting HEP value (21.00,
Table 2) since ribonuclease had no effect on adenylate pools in the absence of shock.
Table 5. Adenine nucleotide assessments after 5 mm of RAO with/without prior myoglobin treatment
ATP
N ATP ADP AMP TAN HEP AEC ADP
RAO/myoglobin 8 1.11
(0.08)
1.54
(0.06)
5.12
(0.09)
7.78
(0.14)
3.77
(0.18)
0.24
(0.01)
0.73
(0.06)
RAO/controls 8 1.21
(0.10)
1.76
(0.06)
5.66
(0.08)
8.64
(0.11)
4.19
(0.13)
0.24
(0.01)
0.70
(0.07)
P — NS <0.05 <0.001 <0.001 NS NS NS
Abbreviations are in Table 1; RAO is renal arterial occlusion.
anything, the antioxidant protocols seemed to worsen the
myoglobin-shock response: the myoglobin-DFO group should
have started with a higher adenylate pooi than the myoglobin
controls, as per Table 1 results. Thus, the LHEP was worsened
by DFO/benzoate treatment (16.07 vs. 12.92 mol/g; P < 0.01).
Recovery experiments
After 30 minutes of recovery from 55 to 60 mm Hg shock,
both the control and myoglobin groups demonstrated almost
normal AEC and ATP/ADP ratios, reflecting near normal
rephosphorylation of residual ADP and AMP to ATP (Table 2,
groups d and e). However, the myoglobin group had statisti-
cally lower absolute ATP, ADP, and hence TAN and HEP,
values than the controls. The LHEP did not significantly differ
between the two groups (using the Table 1, groups c and d data
to calculate LHEP).
Renal blood flow (RBF) responses to shock
Pre-shock RBF for the myoglobin infused rats and their
controls were 5.0 0.4 and 5.3 0.5 ml/min, respectively
(NS). Once reaching the 55 to 60 mm Hg MAP range, RBF
remained very stable for the two groups throughout the shock
period and no significant differences between the two groups
were observed (myoglobin 1.5 0.1; controls 1.6 0.2
ml/min).
Volume controlled hemorrhagic shock experiments
The mean blood withdrawal (per 100 g body wt) necessary to
reach and maintain the 55 to 60 mm Hg range in all of the above
experiments was: myoglobin rats 3.13 0.07; D5W controls
2.44 0.10 (P < 0.01). Because of this difference, the blood
volume controlled hemorrhagic shock experiments were con-
ducted to assess adenylate responses when identical amounts of
blood (2.25 ml/l00 g body wt) were withdrawn from myoglobin
and D5W infused rats.
MAP, although no different for the myoglobin and D5W
groups prior to hemorrhage (myoglobin 128 3; controls 126
3 mm Hg), did differ between the groups during the period of
blood withdrawal. Both the time averaged MAP (for the entire
25 mm period) and the ending MAP, were much higher for the
myoglobin group (Table 3). Despite the higher blood pressures,
the myoglobin treated rats developed much worse adenylate
profiles (Table 3). For example, the loss of HEP (HEP) in
response to blood withdrawal was almost twice as great in the
myoglobin (9.32 imolIg) versus the control (5.18 molIg) group
(P < 0.05).
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Thus, not only did RAO mask an effect of myoglobin on
ischemic adenylate changes, but it also obscured a difference in
the size of the starting adenylate pools.
Renal histology
Fig. 1. A. Renal cortex after completing 25 minutes of hemorrhagic
shock (55 to 60 mm Hg) with only D5W pre-treatment. Normal tubular
morphology is apparent. B. Renal cortex after completing 25 minutes of
hemorrhagic shock (55 to 60 mm Hg) with myoglobin pre-treatment.
Extensive brush border membrane sloughing is seen in virtually every
proximal tubular (SIIS2) segment. In addition, myoglobin is apparent
within several tubular segments.
Ribonuclease experiments
Unlike myoglobin, ribonuclease did not significantly lower
TAN or HEP values in the absence of shock (values NS vs.
those presented in Table 1, group d). However, ribonuclease
pre-treatment did reproduce myoglobin's adverse effect on
ischemic adenylate pools, inducing a LHEP of 13.21 smol/g
(NS vs. myoglobin-shock HEP value of 12.92 molIg). The
ATP and HEP values in the ribonuclease group were 35% and
41% of the control shock values (Table 4). The blood volume
withdrawn from the ribonuclease rats during these experiments
was 2.6 0.14 ml/lOO g.
Renal arterial occlusion (RAO) experiments
No significant difference in ATP or HEP values existed
between the myoglobin and D5W rats subjected to five minutes
of RAO (Table 5). TAN was slightly lower for the myoglobin
group (by 0.86 JLmol/g). However, this undoubtedly reflected
the lower starting TAN in the myoglobin group (12.89 to 10.67
prnol/g, or a difference of 2.22 rmol/g, Table 1, groups a vs. b].
Irrespective of myoglobin or D5W treatment, all kidneys
subjected to the shock protocol showed moderate brush border
bleb formation in outer medullary stripe proximal tubular (S3)
segments. Mild inner medullary stripe vascular congestion was
also observed. These findings did not differ in severity between
the myoglobin and control groups. Three distinctive findings
were observed in the myoglobin plus shock versus shock alone
group: 1) cortical (S1IS2) proximal tubular cells were heme
pigment stained, reflecting myoglobin endocytosis (not obvious
in S3 segments); 2) there was patchy intraluminal myoglobin
cast formation, particularly in distal nephron segments; and 3)
cortical proximal tubular segments showed obvious brush bor-
der bleb formation with these blebs sloughing into tubular
lumina (Fig. IB). This was seen in approximately in 35 to 50%
of Sl/S2 segments but was virtually absent in the D5W treated
shock controls (Fig. 1A). No obvious foci of tubular cell
necrosis were seen in either group of shocked kidneys. No
vascular thromboses or glomerular alterations were observed.
Myoglobin infusion in the absence of shock caused Sl/S2
proximal tubular cell heme staining, myoglobin cast formation,
but no brush border loss/blebbing or other histologic changes.
To confirm that the extent of Sl/S2 brush border blebbing
significantly differed between the groups, this finding was
scored semiquantitatively in each of the kidneys. The following
scoring system was used: 0 = no discernible involvement; 1 + =
<25% of segments involved; 2+ = 25 to 50% of segments
involved; 3+ 50 to 75% of segments involved; and 4+ 75
to 100% of segments involved (entire cortex examined). The
scores were: myoglobin + shock 2.5 0.2; shock alone 0 0;
myoglobin alone 0.2 0,2 (myoglobin + shock, vs. the other
two groups, P < 0.01 by Wilcoxon Rank Sum Test; P < 0.02
after Bonferroni correction).
Creatinine clearance (C) assessments
Ccr for the myoglobin plus shock group, shock only group,
and myoglobin only group were: 0.01 0.006, 1.61 0.03, and
1.25 0.17, respectively (mi/mm). The former significantly
differed from the latter two values (P < 0.001; unpaired
Student's t-test/Bonferroni correction). The latter two were
both within the normal C. range for this laboratory [20].
Discussion
Two laboratories previously have reported that renal adenine
nucleotide pools decrease dramatically during the initiation
phase (0 to 4 hr) of glycerol-induced ARF [8, 9]. Injection of
equal amounts of fructose produced the same adenylate effect,
but, unlike glycerol, fructose did not induce myohemoglobin-
uria [9]. Thus, it was concluded that the adenine nucleotide loss
which follows glycerol or fructose injection is a consequence of
intracellular phosphate trapping (glycero/fructophosphate for-
mation), rather than reflecting a heme pigment reaction [8, 9]. In
contrast, the present study clearly shows that myoglobinuria
can, in fact, have an independent effect on adenine nucleotide
pools since by 65 minutes post-myoglobin infusion, TAN had
declined by 29% in the absence of shock. This TAN decrement
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occurred without a decrease in the AEC or ATPIADP ratio.
Thus, this myoglobin effect is not likely due to heme pigment-
induced renal vasoconstriction/ischemia, because if this were
the case, striking decrements in the AEC and ATPIADP ratio
should have resulted [61. That comparable RBF values were
observed in these myoglobin rats (5.0 ml/min) and their D5W
treated controls (5.3 ml/min) further support the conclusion that
tissue ischemia was not responsible for the falling adenine
nucleotide pools. The exact cause for this adenylate loss cannot
be stated. However, that DFO totally prevented it and that a
non-Fe containing low molecular weight protein (ribonuclease)
did not cause it strongly suggest that Haber Weiss-mediated
hydroxyl radical formation with resultant oxidant tissue damage
was responsible.
Given that myoglobin can adversely affect cellular energetics
under basal conditions, it is not surprising that shock-related
adenylate changes were magnified by prior renal myoglobin
loading. Indeed, the quantitative impact was extraordinarily
dramatic. Whereas 55 to 60 mm Hg shock by itself lowered ATP
by only -25%, in the presence of myoglobin, ATP fell by 85%
of normal values. Not all of this high energy phosphate loss can
be attributed to a shock response, since as noted above,
myoglobin infusion caused a modest decrement in adenylate
pools in the absence of shock. However, even when adjusting
for this pre-shock decrement by calculating the AHEP, at least
three times as much HEP was lost during shock in the myoglo-
bin rats, compared to their D5W treated controls, indicating a
myoglobin-shock synergy. The worsened adenylate pool
change in the myoglobin group is also reflected by significantly
greater reductions in the AEC and ATP/ADP calculations,
compared to the D5W shock controls. Of note, these values
require no correction for pre-shock changes, since, if anything,
they were actually slightly higher in the myoglobin treatment
group.
We considered the possibility that the greater adenylate loss
during shock in the myoglobin rats was mainly due to the
slightly greater blood volume (—1 ml) which needed to be
withdrawn from these rats, compared to controls, to maintain
the 55 to 60 mm Hg MAP range. Therefore, the volume
controlled hemorrhage experiments were conducted. These
experiments excluded this possibility since, once again, far
greater, synergistic, adenylate losses were noted in the myo-
globin treated rats versus the controls (such as, an approximate
doubling of the IHEP). This finding is particularly striking since
the myoglobin group maintained a much higher MAP through-
out the volume-controlled hemorrhage experiments (114 vs. 73
mm Hg, respectively). The higher MAP levels in the myoglobin
group may relate, in part, to oncotic loading induced by
myoglobin infusion. However, that myoglobin treated rats
required somewhat greater blood withdrawal than did ribonu-
clease treated rats (3.1 vs. 2.6 mlIlOO gm) in the pressure-
controlled shock experiments suggests that myoglobin-induced
peripheral vasoconstriction, or an increase in cardiac output,
also may have been operative.
It has been widely suggested that heme pigments can increase
peripheral vascular resistance [10, 11], a possibility raised by
the above observations. Thus, it is tempting to incriminate an
increase in renal vascular resistance as the cause of the en-
hanced high energy phosphate loss in response to shock. For
example, since myoglobin can scavenge nitric oxide (an endo-
thelial derived relaxing factor) [21], increased renal ischemia
might result. Although this is an appealing hypothesis, the data
argue strongly against it. First, we were not able to identify a
significant difference in RBF between the control and myoglo-
bin treated rats either before shock or within the 55 to 60 mm
Hg MAP range. Second, ribonuclease, a non-heme containing
protein (and hence a non-nitric oxide scavenger) induced a
comparable shock-induced loss of adenylate pools. Third, the
myoglobin rats lost a greater amount of adenine nucleotide in
the volume controlled shock experiments than did their D5W
treated counterparts. Since no obvious alterations in renal
vascular responsiveness were noted in the 55 to 60 mm Hg
shock experiments, it is difficult to imagine a lower RBF in the
myoglobin rats during the volume-controlled hemorrhage ex-
periments, given a much higher MAP in the myoglobin versus
the D5W group (mean values of 114 vs. 73 mm Hg, respective-
ly).
Since hydroxyl radical formation has been incriminated by
some as an important mediator of ischemic renal injury [22] and
because tissue Fe loading may accentuate this reaction [5, 14,
15], we tested whether DFO might attenuate the myoglobin-
shock effect on adenine nucleotide pools. A priori, this seemed
like a promising therapeutic intervention since DFO totally
blocked the myoglobin-induced loss of adenine nucleotide in
the absence of shock (Table 1). Despite these considerations,
DFO exerted no protective influence on the myoglobin/shock-
induced adenylate profiles. The addition of an hydroxyl radical
scavenger (Na benzoate) [22] also had no effect. Thus, even
though oxidant injury probably accounts for the basal loss of
adenine nucleotide (Table 1), it is difficult to incriminate this as
the reason for the myoglobin/shock interaction. Indeed, that
ribonuclease reproduced the myoglobin effect on the shock
adenylate profiles virtually proves this contention.
It might be argued that the reason DFO protected against
basal, but not shock, induced adenylate changes is that tissue
oxygen delivery was insufficient during shock to permit hy-
droxyl radical formation. In other words, a myoglobin effect on
adenine nucleotide pools should be expected during a "reper-
fusion" not an "ischemic" period. To test this hypothesis,
post-shock adenylate profiles were assessed in D5W and myo-
globin treated rats. Indeed, the post-shock adenine nucleotide
concentrations were lower in the myoglobin group, compared
to their D5W controls. However, this difference can be totally
explained by the myoglobin effect on adenylate pools indepen-
dent of shock since the LHEP in the recovery period was
virtually identical for the myoglobin and D5W groups (Table 2,
groups d and e). In other words, there was no longer synergistic
ATP depletion, since the loss of adenine nucleotide in the
reflow period could be totally explained by the additive effects
of shock plus myoglobin.
Given that enhanced renal vasoconstriction and oxidant
tissue injury do not appear to explain the myoglobin-induced
potentiation of ischemic adenylate loss, what other mecha-
nism(s) might be operative? One possibility is that endocytic
protein reabsorption, an energy dependent process [23], drains
high energy phosphate during an ischemic period [24]. How-
ever, this seems an unlikely explanation because Ratcliffe et al
[25] showed that myoglobin infusion for 30 minutes before and
during shock had no effect on ischemic adenine nucleotide
content. Pilot studies in our laboratory have indicated that a lag
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time of more than one hour is needed between the start of
myoglobin infusion and the induction of shock to produce
synergistic ATP depletion. If an active transport-mediated
energy drain were responsible for our findings, then a lag time
should not be necessary: the effect should occur once protein
filtration/reabsorption commences (within minutes of protein
infusion). Thus, it appears far more likely that it is tubular cell
protein overload, not endocytic driven ATP utilization, which
in some way accounts for the low molecular weight protein
effect on ischemic adenine nucleotide profiles.
How protein overload sensitizes tubular cells to ATP loss
during shock remains conjectural. This is an exceedingly com-
plex issue to decipher since low molecular weight protein
overload may cause tubular damage even in the absence of
ischemia [23, 26]. Without knowing how low molecular weight
protein overload independently affects tubular cell function and
viability (an issue unresolved in the literature), it is extremely
difficult to state how it predisposes to adenylate depletion
during shock. It cannot even be stated whether the exaggerated
ATP loss during shock is a primary or a secondary event. All
that can be concluded is that myoglobin plus shock induce
synergistic HEP depletion, synergistic Sl/S2 morphologic dam-
age, and synergistic functional impairment, as assessed by CCr.
Whether the exaggerated HEP loss contributed to that in-
creased functional/morphologic damage or whether it was pri-
marily a reflection of it cannot be stated. However, given the
fact that a toxic/ischemic synergy undoubtedly represents a
cascade of interactive factors, it seems highly likely that the
greatly exaggerated HEP loss could have played a role in the
potentiation of the Sl/S2 tubular cell damage noted in these
experiments, particularly since heme pigments preferentially
accumulate in Sl/S2 segments [4, 22].
A final goal of this study was to test our hypothesis that RAO
may be an inadequate experimental model of ARF if one is
interested in studying cellular energetics in clinically relevant
forms of ischemic renal damage. Because RAO represents a
total ischemic insult, it seemed likely to us that it could
overwhelm other potential influences on cellular energetics. If
so, then extrapolation of adenine nucleotide data obtained from
the RAO model to shock-related ischemic renal injury could
yield erroneous conclusions. Our experience with low molecu-
lar weight protein infusion during RAO and shock confirms this
viewpoint. As noted above, we previously observed [31 that
ribonuclease pre-treatment had no impact on RAO-induced
adenylate profiles. In the present study, ATP/HEP content did
not significantly differ between myoglobin and control rats
subjected to five minutes of RAO, despite the fact myoglobin
infusion independently lowers adenylate pools. Based on these
RAD results, both past and present, one would conclude that
low molecular weight proteins have no influence on ischemic
adenylate profiles. Clearly, although this conclusion is true for
RAO, it cannot be extrapolated to ischemia, in general, since
during shock, ribonuclease and myoglobin each induced a
dramatic lowering of HEP concentrations. Thus, caution is
clearly needed when using RAO as a model for studying
ischemic cellular energetics.
In conclusion, myoglobin can have a dramatic impact on
renal adenylate pools. In the absence of shock, it causes a
modest, time dependent reduction in TAN content without
reducing RBF. That this effect is blocked by DFO and that it is
not reproduced by ribonuclease (a non-Fe containing protein)
strongly suggest that it is caused by Fe driven oxidant tissue
damage. During mild (volume controlled experiments) or mod-
erate (55 to 60 mm Hg experiments) hemorrhagic shock, myo-
globin drastically potentiates renal high energy phosphate de-
pletion. This effect is not Fe dependent since it is reproduced by
ribonuclease and because DFO/Na benzoate confer no protec-
tion. The underlying mechanism for these shock-induced
changes appears to have a tubular cell, rather than a hemody-
namic basis, relating in some way to tubular cell protein
overload. Despite the fact that both myoglobin and ribonucle-
ase have dramatic, and comparable, impacts on shock-induced
adenylate changes, neither alters RAO-induced adenine nude-
otide profiles. These findings indicate that: 1) caution is needed
when extrapolating adenine nucleotide results obtained with the
RAO model to shock-induced adenylate changes; and 2) not all
renal myoglobin effects can be attributed to Fe-mediated tissue
injury since non-Fe containing proteins may exert identical
adverse effects.
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